Ownership and insider activity for Nurix Therapeutics, Inc. (NRIX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Price
| Price | $26.80 (closing price, October 30, 2026) |
| Market Cap | $2.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-15 | Hansen Gwenn | M-Exempt | 1,452 | $3K |
| 2026-10-15 | Hansen Gwenn | S-Sale | 1,452 | $36K |
| 2026-10-15 | Hansen Gwenn | M-Exempt | 1,452 | $3K |
| 2026-10-14 | GREGORY JULIA P | M-Exempt | 22,583 | $42K |
| 2026-10-14 | GREGORY JULIA P | S-Sale | 22,583 | $529K |
| 2026-10-14 | GREGORY JULIA P | M-Exempt | 22,583 | $42K |
| 2026-10-02 | Ring Christine | M-Exempt | 5,786 | $50K |
| 2026-10-02 | Ring Christine | M-Exempt | 5,786 | $50K |
| 2026-10-02 | Ring Christine | S-Sale | 5,786 | $134K |
| 2026-09-02 | Ring Christine | M-Exempt | 5,787 | $50K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.6M | $34.8M | $119.4M | $80.5M | $64.5M | $54.6M | $110.0M | $247.0M |
| Short-term Investments | $13.4M | $2.9M | $161.8M | $215.2M | $244.7M | $233.3M | $499.6M | $346.0M |
| Receivables | 0 | 0 | $11.3M | $6.2M | $1.1M | $800,000 | $1.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | -$1.1M | 0 | 0 | 0 |
| Total Current Assets | $40.7M | $39.4M | $298.4M | $311.1M | $318.4M | $295.5M | $619.4M | $606.8M |
| Property, Plant & Equipment | $4.4M | $3.9M | $6.7M | $25.3M | $29.5M | $48.0M | $45.9M | $73.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $45.4M | $44.0M | $396.3M | $476.8M | $416.8M | $355.6M | $669.3M | $688.1M |
| Accounts Payable | $1.3M | $1.6M | $3.4M | $6.7M | $5.1M | $6.4M | $11.5M | $11.2M |
| Short-term Debt | 0 | 0 | 0 | $3.8M | $5.5M | $7.5M | 0 | 0 |
| Total Current Liabilities | $32.8M | $16.1M | $44.5M | $66.3M | $70.7M | $87.0M | $95.9M | $86.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $34.0M | $53.6M | $106.1M | $134.5M | $113.1M | $155.1M | $142.3M | $149.4M |
| Retained Earnings | -$38.8M | -$60.5M | -$103.7M | -$220.9M | -$401.3M | -$545.2M | -$738.8M | -$1.00B |
| Total Equity | -$36.8M | -$57.7M | $290.3M | $342.3M | $303.7M | $200.5M | $527.0M | $538.7M |
| Total Debt | 0 | 0 | 0 | $13.0M | $12.0M | $30.6M | $28.3M | $55.7M |
| Net Debt | -$39.0M | -$37.7M | -$281.1M | -$282.7M | -$297.2M | -$257.3M | -$581.3M | -$537.2M |
| Working Capital | $7.8M | $23.2M | $253.9M | $244.9M | $247.8M | $208.5M | $523.5M | $520.3M |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 8.44 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.50 |
Profitability
| Return on Equity | 49.34% |
| Return on Invested Capital | 25.95% |
| Return on Assets | 24.67% |
| Gross Margin | 86.50% |
| Operating Margin | 41.27% |
| Net Margin | 42.01% |
Related companies: RVMD · KYMR · TNGX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of NRIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks